Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan A Burger

Showing results (131-140 of 223) with videos related to

Pageof 23
Sort By:
Blood|August 2, 2011
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemiaJulia Hoellenriegel, Sarah A Meadows, Mariela Sivina, et al.
Haematologica|March 26, 2016
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinibCandida Vitale, Inhye E Ahn, Mariela Sivina, et al.
Blood|July 5, 2011
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemiaXavier C Badoux, Michael J Keating, Sijin Wen, et al.
Leukemia|February 27, 2018
Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemiaPaolo Strati, Alessandra Ferrajoli, William G Wierda, et al.
British Journal of Haematology|July 26, 2019
The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotypePaolo Strati, Feng Wang, Francesco P Tambaro, et al.
Blood|March 11, 2015
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemiaJennifer R Brown, Jacqueline C Barrientos, Paul M Barr, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 19, 2016
Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic LeukemiaElisa Ten Hacken, Mariela Sivina, Ekaterina Kim, et al.
Blood|September 21, 2019
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapyPhilip A Thompson, Jaya Srivastava, Christine Peterson, et al.
Oncotarget|September 23, 2016
A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLLNitin Jain, Kumudha Balakrishnan, Alessandra Ferrajoli, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 25, 2019
STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival AdvantageUri Rozovski, David M Harris, Ping Li, et al.
Pageof 23

Showing results (131-140 of 223) with videos related to

Sort By:
Pageof 23
Blood|August 2, 2011
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemiaJulia Hoellenriegel, Sarah A Meadows, Mariela Sivina, et al.
Haematologica|March 26, 2016
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinibCandida Vitale, Inhye E Ahn, Mariela Sivina, et al.
Blood|July 5, 2011
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemiaXavier C Badoux, Michael J Keating, Sijin Wen, et al.
Leukemia|February 27, 2018
Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemiaPaolo Strati, Alessandra Ferrajoli, William G Wierda, et al.
British Journal of Haematology|July 26, 2019
The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotypePaolo Strati, Feng Wang, Francesco P Tambaro, et al.
Blood|March 11, 2015
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemiaJennifer R Brown, Jacqueline C Barrientos, Paul M Barr, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 19, 2016
Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic LeukemiaElisa Ten Hacken, Mariela Sivina, Ekaterina Kim, et al.
Blood|September 21, 2019
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapyPhilip A Thompson, Jaya Srivastava, Christine Peterson, et al.
Oncotarget|September 23, 2016
A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLLNitin Jain, Kumudha Balakrishnan, Alessandra Ferrajoli, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 25, 2019
STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival AdvantageUri Rozovski, David M Harris, Ping Li, et al.
Pageof 23